Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022

摘要

This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.

This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis.

(需要透過 WebFetch 補充或人工審核來提取關鍵發現)

萃取時間: 2026-02-05T15:12:47Z 資料來源: CDC MMWR